Metacrine, Inc. (NASDAQ:MTCR – Get Rating) CEO Preston Klassen sold 380,605 shares of the company's stock in a transaction that occurred on Thursday, January 26th. The stock was sold at an average price of $0.41, for a total value of $156,048.05. Following the completion of the sale, the chief executive officer now owns 541,905 shares of the company's stock, valued at $222,181.05. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Metacrine Stock Performance

MTCR opened at $0.48 on Monday. The company has a market capitalization of $20.44 million, a price-to-earnings ratio of -0.47 and a beta of -0.92. The company has a debt-to-equity ratio of 0.34, a current ratio of 12.15 and a quick ratio of 12.15. Metacrine, Inc. has a 1-year low of $0.30 and a 1-year high of $0.68. The business has a 50 day moving average price of $0.43 and a two-hundred day moving average price of $0.45.

Metacrine (NASDAQ:MTCR – Get Rating) last released its earnings results on Monday, November 14th. The company reported ($0.13) earnings per share for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.02). Research analysts predict that Metacrine, Inc. will post -0.62 EPS for the current fiscal year.

Analysts Set New Price Targets

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. State Street Corp increased its holdings in shares of Metacrine by 482.8% in the second quarter. State Street Corp now owns 72,186 shares of the company's stock valued at $36,000 after buying an additional 59,800 shares in the last quarter. Citadel Advisors LLC increased its holdings in shares of Metacrine by 112.5% in the third quarter. Citadel Advisors LLC now owns 136,606 shares of the company's stock valued at $66,000 after buying an additional 72,306 shares in the last quarter. Jane Street Group LLC bought a new position in shares of Metacrine in the third quarter valued at $84,000. Bank of New York Mellon Corp bought a new position in shares of Metacrine in the first quarter valued at $126,000. Finally, Bank of America Corp DE increased its holdings in shares of Metacrine by 10.5% in the first quarter. Bank of America Corp DE now owns 263,340 shares of the company's stock valued at $161,000 after buying an additional 24,964 shares in the last quarter. Institutional investors own 34.28% of the company's stock.

Metacrine Company Profile

(Get Rating)

Metacrine, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc was incorporated in 2014 and is headquartered in San Diego, California.

Recommended Stories

• Get a free copy of the StockNews.com research report on Metacrine (MTCR)
• Is Seagate Technology Signaling the End of its Normalization?
• eHealth Stock Rises from the Ashes. Time to Get In?
• Can Yext A.I. Search Platform Drive Growth in 2023?
• Cassava Sciences Stock Undervalued with Its $124 Price Target?
• Constellation Brands: Are Consumers Trading Down for Rail Drinks?

Receive News & Ratings for Metacrine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metacrine and related companies with MarketBeat.com's FREE daily email newsletter.